New drug combo aims to deeply suppress CLL with smarter, shorter treatment
NCT ID NCT05677919
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This study tests a combination of two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this treatment can reduce cancer to very low levels, measured by a sensitive blood test. The length of treatment is guided by this test, aiming to personalize therapy and potentially limit side effects. About 72 adults will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.